Kiwi for Health & Longevity - Quick Reference Sheet

Kiwi for Health & Longevity

Created on 10/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 3.1 – Audit

Kiwi is an edible berry eaten for digestive regularity, vitamin C levels, and blood pressure support. Two whole green or gold kiwifruits daily relieve chronic constipation more comfortably than psyllium fiber, whereas encapsulated extracts fail. Three green kiwifruits daily modestly lower elevated blood pressure, while whole fruit lowers artery-clogging cholesterol, blunts mealtime glucose spikes, shortens colds, and improves mood when vitamin C is low. (Full Review)

Protocol

Digestive regularity and motility protocol
2 large peeled green 'Hayward' kiwifruits daily
~150–200 g edible flesh daily (1 fruit twice daily with meals or 2 at breakfast); whole fruit outperforms encapsulated extracts (575–2,400 mg/day)
Vitamin C, mood, and skin protocol
2 SunGold kiwifruits daily
~160–200 g flesh (~250 mg vitamin C) daily; restores saturating plasma and tissue ascorbate in adults with suboptimal baseline vitamin C (<40 μmol/L)
Vascular and platelet protocol
3 green kiwifruits daily for 4–8 weeks
Lowers 24-hour ambulatory blood pressure and platelet aggregation; taken with meals for glucose and amino acid effects, or 60 minutes before bed for sleep
Time to effect
Laxation and mood
4–14 days
Laxation improves in 4–14 days with reduced straining and bloating during weeks 1–4; mood and vitality improve in 4–16 days when baseline vitamin C is suboptimal
Blood pressure and skin density
4–8 weeks
Lowers 24-hour ambulatory blood pressure and platelet aggregation while saturating plasma and dermal vitamin C stores
Glycemic and leucine effects
Acute
Blunts 30-minute postprandial glucose excursion when replacing refined starch and accelerates plasma leucine appearance with dietary protein

Benefits

Contraindications
  • Confirmed IgE-mediated allergy to kiwifruit (Act d 1 to Act d 13) or history of systemic anaphylaxis to Actinidia species
  • Latex-fruit syndrome with clinical cross-reactivity to kiwifruit
  • Uncompensated hyperkalemia or advanced chronic kidney disease requiring strict dietary potassium restriction
  • Severe enteric hyperoxaluria or recurrent calcium oxalate kidney stones advised to restrict dietary oxalate
Key Interactions
  • Prescription antihypertensive medications (lisinopril, losartan, amlodipine): Monitor (theoretical)
  • Prescription antiplatelet and anticoagulant drugs (clopidogrel, rivaroxaban, apixaban): Caution (theoretical)
  • Vitamin K antagonist anticoagulants (warfarin, acenocoumarol): Monitor (theoretical)
  • Potassium-sparing diuretics and renin-angiotensin-aldosterone system (RAAS, hormone pathway regulating blood pressure and potassium) blockers (spironolactone, eplerenone, lisinopril): Caution (theoretical)
  • Over-the-counter nonsteroidal anti-inflammatory drugs and salicylates (aspirin, ibuprofen, naproxen): Caution (theoretical)
  • Over-the-counter bulk-forming and osmotic laxatives (psyllium husk, polyethylene glycol 3350, magnesium hydroxide): Monitor (theoretical)
  • Antihypertensive and antiplatelet supplements (aged garlic extract, omega-3 fatty acids, nattokinase, L-citrulline): Monitor (theoretical)
  • High-dose vitamin C and calcium supplements (ascorbic acid, calcium citrate): Monitor (theoretical)
  • Cytochrome P450 substrate medications (midazolam, atorvastatin, dextromethorphan): Monitor (theoretical)
  • Vigorous post-meal exercise: Caution

Risk & Side Effects

  • High: Immunoglobulin E-mediated oral allergy syndrome and systemic anaphylaxis
  • Medium:
  • Low: Mild gastrointestinal distension and loose stools
  • Speculative: Non-allergic oral mucosal irritation; dietary oxalate load in calcium oxalate kidney stone formers; excessive bleeding time prolongation; hyperkalemia in advanced renal insufficiency

Monitoring

Marker Target Why
Weekly CSBMs and BSFS ≥3 CSBMs (complete spontaneous bowel movements)/week and increase of ≥1 CSBM/week from baseline; BSFS (Bristol Stool Form Scale) Types 3–4 (Rome IV trial criteria, Gearry et al., 2023) Efficacy marker expected to change: quantifies laxation response and stool normalization.
24-Hour Ambulatory or Seated Blood Pressure <130/80 mmHg (Svendsen et al., 2015 normotensive threshold); or track reduction from individual baseline Efficacy and safety marker: tracks expected blood pressure reduction and screens for hypotension.
Fasting Lipid Panel (LDL, HDL, Triglycerides) No established target; track change in LDL, HDL, and triglycerides from individual baseline Efficacy marker expected to change: assesses LDL reduction and APOE4-linked triglyceride and HDL shifts.
Plasma Ascorbic Acid (Vitamin C) ≥70 μmol/L saturating concentration (Carr et al., 2012; Pullar et al., 2026) Efficacy marker expected to change: confirms systemic and tissue vitamin C saturation.
Serum Potassium and eGFR Potassium 3.5–5.0 mmol/L (standard reference range); eGFR (estimated glomerular filtration rate) ≥90 mL/min/1.73 m² (standard reference range) Safety check: identifies hyperkalemia or renal impairment that stops or reduces high-dose intake.

Cadence: Baseline (including a 2-week daily bowel diary); weeks 1 and 4 for gastrointestinal symptom response and serum potassium (with eGFR at week 4); weeks 4 and 8 for blood pressure and plasma vitamin C saturation; after 8–12 weeks and every 3–6 months for fasting lipids and long-term adherence.

Qualitative Assessment

  • Digestive comfort: Reduced straining and bloating during weeks 1–4.
  • Subjective vitality: Improved daytime vigor and reduced fatigue within 1–2 weeks.
  • Sleep quality: Shorter sleep latency and higher morning alertness.
  • Oral tolerance: Absence of tongue stinging or lip itching.